DexCom, Inc.
Clinical trials sponsored by DexCom, Inc., explained in plain language.
A medical device company specializing in continuous glucose monitoring systems for diabetes.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a smart glucose monitor help type 2 diabetes patients on insulin? Results expected Nov 2026 (estimated)
-
Could a simple monitor transform blood sugar control for millions with type 2 diabetes?
Disease control OngoingThis study tests whether using a continuous glucose monitor (CGM) helps adults with type 2 diabetes who do not take insulin improve their blood sugar control. Participants are randomly assigned to either use a real-time CGM or receive routine care with occasional blinded CGM wear…
Sponsor: DexCom, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Smart insulin dosing system aims to simplify diabetes management
Disease control OngoingThis study tests a system that combines a continuous glucose monitor (CGM) with daily insulin dose recommendations for people with type 2 diabetes who are starting basal insulin. Participants wear a Dexcom CGM sensor and receive suggested insulin doses through the DexBasal system…
Phase 1 • Sponsor: DexCom, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Can a smart glucose monitor help type 2 diabetes patients on insulin?
Disease control OngoingThis study is testing whether a real-time continuous glucose monitor (CGM) can help 200 adults with type 2 diabetes who use insulin in Saudi Arabia. Participants wear a CGM device that tracks blood sugar levels continuously. The main goal is to see if it improves HbA1c, a measure…
Phase 4 • Sponsor: DexCom, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Can a wearable glucose monitor improve daily diabetes care? a 5,000-Person study seeks answers
Knowledge-focused OngoingThis study follows 5,000 people with diabetes who use a Dexcom continuous glucose monitoring (CGM) system in their daily routine. Researchers will track how the device performs when used as labeled and ask participants to complete questionnaires over four years. The goal is to un…
Sponsor: DexCom, Inc. • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC